The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Sorafenib: A Review in Hepatocellular Carcinoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H. L., O'Beirne, J., Fox, R., Skowronska, A., Palmer, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9151 · Cited by 2,783
Benson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., & Carter, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1377 · Cited by 1,536
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Cheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Lencioni, R., Llovet, J. M., Han, G., Tak, W. Y., Yang, J., Guglielmi, A., Paik, S. W., Reig, M., Kim, D. Y., Chau, G.-Y., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.012 · Cited by 694
Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 576
Kudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.-Y., Takayama, T., Yoon, J.-H., Hori, T., Kumada, H., Hayashi, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.007 · Cited by 570
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Llovet, J. M., Peña, C. E. A., Lathia, C. D., Shan, M., Meinhardt, G., & Bruix, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2175 · Cited by 559
Adnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(05)07047-3 · Cited by 463
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Llovet, J. M., & Hernandez-Gea, V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0547 · Cited by 397
Marrero, J. A., Kudo, M., Venook, A. P., Ye, S.-L., Bronowicki, J.-P., Chen, X.-P., Dagher, L., Furuse, J., Geschwind, J.-F. H., de Guevara, L. L., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.020 · Cited by 385
Verslype, C., Rosmorduc, O., & Rougier, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds225 · Cited by 365
Iavarone, M., Cabibbo, G., Piscaglia, F., Zavaglia, C., Grieco, A., Villa, E., Cammà, C., & Colombo, M. (2010) · Hepatology · doi:10.1002/hep.24644 · Cited by 352
Cheng, A.-L., Guan, Z., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Yang, T.-S., Tak, W. Y., Pan, H., Yu, S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.006 · Cited by 259
Chen, J., Jin, R., Zhao, J., Liu, J., Ying, H., Yan, H., Zhou, S., Liang, Y., Huang, D., Liang, X., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.019 · Cited by 251
Lencioni, R., Kudo, M., Ye, S. ‐., Bronowicki, J. ‐., Chen, X. ‐., Dagher, L., Furuse, J., Geschwind, J. F., Guevara, L. L., Papandreou, C., et al. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12352 · Cited by 223
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics
Lathia, C., Lettieri, J., Cihon, F., Gallentine, M., Radtke, M., & Sundaresan, P. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0068-6 · Cited by 212
Challenges of advanced hepatocellular carcinoma
Colagrande, S., Inghilesi, A. L., Aburas, S., Taliani, G. G., Nardi, C., & Marra, F. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i34.7645 · Cited by 177
Chen, K.-F., Tai, W.-T., Liu, T.-H., Huang, H.-P., Lin, Y.-C., Shiau, C.-W., Li, P.-K., Chen, P.-J., & Cheng, A.-L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3389 · Cited by 172
Tai, W.-T., Cheng, A.-L., Shiau, C.-W., Huang, H.-P., Huang, J.-W., Chen, P.-J., & Chen, K.-F. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.047 · Cited by 158
Sansonno, D. E., Lauletta, G., Russi, S., Conteduca, V., Sansonno, L., & Dammacco, F. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0313 · Cited by 158
Pressiani, T., Boni, C., Rimassa, L., Labianca, R., FAGIUOLI, S., Salvagni, S., Ferrari, D., Cortesi, E., Porta, C., Mucciarini, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds343 · Cited by 154
Ren, Z.-G., Zhu, K.-S., Kang, H., Lu, M.-Q., Qu, Z., Lu, L., Song, T.-Q., Zhou, W.-P., Wang, H., Yang, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9651 · Cited by 152
Raoul, J., Bruix, J., Greten, T. F., Sherman, M., Mazzaferro, V., Hilgard, P. A., Scherübl, H., Scheulen, M. E., Germanidis, G. S., Dominguez, S., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.009 · Cited by 131
Chen, M., Yan, B., Lu, W., Chen, M., Yu, S., Yang, P., & Ann‐Lii, C. (2013) · International Journal of Cancer · doi:10.1002/ijc.28362 · Cited by 130
Cao, M., Xu, Y., Youn, J., Cabrera, R., Zhang, X., Gabrilovich, D. I., Nelson, D. R., & Liu, C. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2010.205 · Cited by 129
Geschwind, J.-F. H., Kudo, M., Marrero, J. A., Venook, A. P., Chen, X., Bronowicki, J., Dagher, L., Furuse, J., de Guevara, L. L., Papandreou, C. N., et al. (2016) · Radiology · doi:10.1148/radiol.2015150667 · Cited by 120
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
Hollebecque, A., Cattan, S., Romano, O., Sergent, G., Mourad, A., Louvet, A., Dharancy, S., Boleslawski, E., Truant, S., Pruvot, F., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04860.x · Cited by 119
Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma
Swamy, S. G., Kameshwar, V. H., Shubha, P. B., Looi, C. Y., Shanmugam, M. K., Arfuso, F., Dharmarajan, A., Sethi, G., Shivananju, N. S., & Bishayee, A. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0452-7 · Cited by 114
Lencioni, R. A., Kudo, M., Ye, S.-L., Bronowicki, J., Chen, X.-P., Dagher, L., Furuse, J., Geschwind, J. F., de Guevara, L. L., Papandreou, C. N., et al. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02940.x · Cited by 111
Cheng, A., Thongprasert, S., Lim, H. Y., Sukeepaisarnjaroen, W., Yang, T., Wu, C., Chao, Y., Chan, S. L., Kudo, M., Ikeda, M., et al. (2016) · Hepatology · doi:10.1002/hep.28600 · Cited by 100
Abou‐Alfa, G. K., Niedzwieski, D., Knox, J. J., Kaubisch, A., Posey, J. A., Tan, B. R., Kavan, P., Goel, R., MURRAY, J. J., Bekaii‐Saab, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.192 · Cited by 100
Ogasawara, S., Chiba, T., Ooka, Y., Suzuki, E., Kanogawa, N., Saito, T., Motoyama, T., Tawada, A., Kanai, F., & Yokosuka, O. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0292-9 · Cited by 89
Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma
Nishida, N., Kitano, M., Sakurai, T., & Kudo, M. (2015) · Digestive Diseases · doi:10.1159/000439102 · Cited by 83
Sonntag, R., Gaßler, N., Bangen, J.-M., Trautwein, C., & Liedtke, C. (2014) · Cell Death and Disease · doi:10.1038/cddis.2013.557 · Cited by 77
Kudo, M., Lencioni, R. A., Marrero, J. A., Venook, A. P., Bronowicki, J., Chen, X., Dagher, L., Furuse, J., Geschwind, J. H., de Guevara, L. L., et al. (2016) · Liver International · doi:10.1111/liv.13096 · Cited by 50
Kudo, M., Ikeda, M., Takayama, T., Numata, K., Izumi, N., Furuse, J., Okusaka, T., Kadoya, M., Yamashita, S., Ito, Y., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1204-2 · Cited by 48
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
Cheng, A., Hsu, C., Shen, Y., Shao, Y., & Hsu, C. (2014) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s45040 · Cited by 35
Ye, S.-L., Chen, X., Yang, J., Bie, P., Zhang, S., Liu, F., Liu, L., Zhou, J., Dou, K., Hao, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6781 · Cited by 24
Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma
Costanzo, G. G. D., Tortora, R., Morisco, F., Addario, L., Guarino, M., Cordone, G., Falco, L., & Caporaso, N. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0454-5 · Cited by 23
Cited by
Macrophage Polarization and Its Role in Liver Disease
Wang, C., Ma, C., Gong, L., Guo, Y., Fu, K., Zhang, Y., Zhou, H., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803037 · Cited by 581
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Mechanisms of hepatocellular carcinoma progression
Ogunwobi, O. O., Harricharran, T., Huaman, J., Galuza, A., Odumuwagun, O., Tan, Y., Ma, G. X., & Nguyen, M. T. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i19.2279 · Cited by 291
Metadata
- Authors
- Keating, G. M.
- Venue
- Targeted Oncology
- Published
- 2017-03-15
- Volume
- 12
- Issue
- 2
- Pages
- 243-253
- ISSN
- 1776-2596 (ISSN-L)
- 1776-260X
- OpenAlex
- W2601148710
- Cited by
- 308
- References
- 55
- FWCI
- 14.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.